# Neutralization Activity of Standard and Hyperimmune Intravenous Immunoglobulins Against Recently Circulating SARS-CoV-2 Variants

**Authors:** Dongxiao Liu, Lorenza Bellusci, Hana Golding, Surender Khurana

PMC · DOI: 10.3390/vaccines13070760 · Vaccines · 2025-07-17

## TL;DR

New IVIG lots from 2023-2024 can neutralize recent SARS-CoV-2 variants like KP.3 and XEC, which older treatments cannot.

## Contribution

Shows recent IVIG lots contain antibodies effective against new Omicron subvariants.

## Key findings

- IVIG lots from 2023–2024 neutralize KP.3 and XEC variants.
- Older IVIG and convalescent plasma are ineffective against these variants.
- Recent IVIG may offer protection against current SARS-CoV-2 strains.

## Abstract

Our study demonstrates that IVIG lots manufactured in 2023–2024 contain neutralizing antibodies against circulating Omicron variants, including KP.3 and XEC. These variants are resistant to all convalescent plasma and IVIG preparations produced prior to 2023. Therefore, recent IVIG lots may provide some protection against COVID-19 caused by circulating SARS-CoV-2 variants.

## Linked entities

- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** COVID-19 (MESH:D000086382)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12299002/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12299002/full.md

## References

12 references — full list in the complete paper: https://tomesphere.com/paper/PMC12299002/full.md

---
Source: https://tomesphere.com/paper/PMC12299002